NCT06441708

Brief Summary

Aim of the work: To determine the killing ability of neutrophils to ATCC 27853, carbapenem-resistant P. aeruginosa. To compare between the ability of ATCC 27853, carbapenem-resistant P. aeruginosa to induce NETs formation. To quantify NETS formation in response to PMA, ATCC 27853, carbapenem-resistant P. aeruginosa using immunofluorescence. To determine the killing ability of NETs on ATCC 27853, carbapenem-resistant P. aeruginosa.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2024

Completed
3 days until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 4, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

June 4, 2024

Status Verified

June 1, 2024

Enrollment Period

1 year

First QC Date

May 29, 2024

Last Update Submit

June 3, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Quantitification of neutrophils extracellular traps by immunofluroscrnce

    Quantitification of neutrophils extracellular traps by indirect immunofluroscrnce

    Three months

Interventions

No intervention on patient

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Clinical isolates from different clinical samples including urine, blood, sputum, wound

You may qualify if:

  • isolates will be isolated from different clinical samples including wound respiratory tract urine and blood. \_carbapenem-resistant P. aeruginosa isolates.

You may not qualify if:

  • \_carbapenem-sensitive P. aeruginosa isolates.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Noura Samir Hussein, Assistant lecturer

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer at medical Microbilogy and Immunology department

Study Record Dates

First Submitted

May 29, 2024

First Posted

June 4, 2024

Study Start

June 1, 2024

Primary Completion

June 1, 2025

Study Completion

July 1, 2025

Last Updated

June 4, 2024

Record last verified: 2024-06